Associations of IL-6, CRP, and fibrinogen (HR for 1-unit increase in log IL-6, log CRP, and fibrinogen) of experiencing one of four categories of events by baseline treatment allocation.

Event groupings as defined in the methods. Fatal CVD deaths preceded by nonfatal CVD are excluded. p-Value is for interaction between randomized treatment allocation and marker. Unadjusted HR (95% CIs) are presented.事件分组规则遵循研究方法中的明确定义。排除存在非致命心血管疾病（Cardiovascular Disease, CVD）既往史的致命心血管疾病死亡病例。本次报告的P值用于检验随机治疗分配与生物标志物之间的交互效应。本研究展示未经校正的风险比（Hazard Ratio, HR）及其95%置信区间（Confidence Interval, CI）。